Valneva SE (VLA)
Euronext
Closed
Aug 25, 2026
Day's Range
2.8052 wk Range
2.03Overview - VLA - Valneva SE
Key Statistics
Valuation
Enterprise Value
651.19M
P/E (Trailing)
‪70.64‬
P/E (Forward)
‪19.25‬
PEG Ratio
‪0.35‬
Price / Sales (TTM)
‪3.93‬
Price / Book
‪6.89‬
EV / EBITDA
‪-6.59‬
Profitability
Gross Margin
‪15.28%‬
Profit Margin
‪-110.29%‬
Operating Margin
‪-74.91%‬
Return on Assets
‪-16.68%‬
Return on Equity
‪-117.84%‬
Ownership
Shares Outstanding
173.75M
Float
157.26M
Held by Insiders
‪10.72%‬
Held by Institutions
‪24.41%‬
Price stats
Beta
‪1.34‬
50-Day Avg
‪2.33‬
200-Day Avg
‪3.21‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
8 analysts
Average price target
‪€ 6.19‬Peers - VLA - Valneva SE
Peer Comparison
Compared with companies in Biotechnology listed on Euronext.
Profile Summary - VLA - Valneva SE
About
Valneva SE is a specialty vaccine company headquartered in Saint-Herblain, France, that develops, manufactures, and commercializes prophylactic vaccines targeting infectious diseases with significant unmet medical needs. Its commercial portfolio features three key vaccines: IXIARO®, for Japanese encephalitis;…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
